Thermo Fisher Scientific has entered into a license agreement to incorporate its BRAHMS biomarker assays on Alere’s point-of-care Triage platform.
Thermo Scientific BRAHMS Procalcitonin (PCT) test on the Triage platform facilitates the early detection of sepsis in critically ill patients.
Thermo Fisher Scientific president and CEO Marc Casper said improving patient care while reducing the cost of diagnosing disease provides a much needed boost to hospitals struggling to maintain service levels and remain competitive.
Alere plans to integrate Thermo Scientific’s BRAHMS Copeptin, MR-proADM and MR-proANP on its Triage system.
These biomarkers are used to diagnose patients who experience symptoms such as chest pains or shortness of breath and seek treatment in a hospital emergency room.